INTRODUCTION
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults as well as the most malignant glioma. The median survival of 12 to 15 months 1 shows that it is among the most aggressive of human neoplasms. To date, no prognostic biomarker has been found to be sufficiently reliable to be useful for clinical practice. Brainresident macrophages, also called microglia, infiltrate GBM and may account for up to one third of the tumor mass.
2,3 Immunohistochemical markers have made it possible to identify four subtypes of these highly polymorphous microglial cells.
2 These cells are key components of the inflammatory reaction that defends against brain neoplasms, but their specific role in this antitumor immune response is poorly understood. Indeed, little evidence supports the existence of antitumor functions; 4 much more data suggest that microglial cells may promote tumors. 5, 6 Tumor cells may compromise and control microglial functions, using them for their own growth and invasion.
Chemokines are one of the factors secreted by the tumor that may affect its environment. This family of structurally related chemotactic cytokines directs the migration of leukocytes throughout the body. The chemokine CCL2, also named MCP-1 (monocyte chemoattractant protein 1), was initially isolated from a human glioblastoma cell line 7 and has been associated with glioma aggressiveness. [8] [9] [10] [11] It mobilizes macrophages and microglial cells by activating its cognate receptor CCR2.
12 CCR2, together with CX3CR1, which is the receptor for the chemokine CX3CL1, makes it possible to identify two functional subsets of blood monocytes: the inflammatory monocytes that express both receptors and the noninflammatory monocytes that express only CX3CR1. 13 Recent experiments with a transgenic mouse model suggest that increased CX3CR1 signaling activity protects against microglial neurotoxicity.
14 Moreover, we recently showed that CX3CR1-dependent subretinal microglial cell accumulation leads to cardinal features of age-related macular degeneration. 15 The role of these chemokines and their receptors in brain tumors is not known.
We previously identified two common single-nucleotide polymorphisms (SNPs) in the open reading frame of the CX3CR1 gene, called V249I and T280M, 16 associated with a reduced risk of myocardial infarction 17, 18 and an increased risk of age-related macular degeneration, 15 probably because of their functional impact on monocyte adherence and migration. 15, 19 Another polymorphism in the distal regulatory region of the CCL2 gene (CCL2-G2518) modulates CCL2 production 20 and is associated with a reduced risk of severe coronary artery diseases. 21 The pathophysiologic impact of these polymorphisms seems to be due to their alteration of the mobilization and activation of myeloid lineage cells. Accordingly, we postulated that these variants may be associated with GBM risk or survival. Because of their functional relevance in monocyte migration and activation and because these variant are tagged SNPs and thus representative of polymorphisms within high-linkage disequilibrium region, we restricted our investigations to this set of genetic variants in a prospective and in a retrospective series of patients with GBM.
METHODS

Patients
We studied two groups of patients and one group of healthy control individuals. Patients in both groups met the following inclusion criteria: histologic diagnosis of pure primary glioblastoma (WHO grade 4) without previous history of glial tumor, age Ն 18 years, clinical data and follow-up available in the prospective neuro-oncology database, blood DNA available, and written informed consent. The racial classification was self-reported. All tumors were reviewed by two pathologists (K.M. and A.R.) to confirm the diagnosis. Group 1 is a prospective series starting in 1997 composed of 230 patients with GBM (Laboratoire de Biologie des Interactions Neurones et Glie, Inserm U711, Paris, France) as previously reported. 22 Group 2 is a retrospective series of 106 patients with surgical treatment of GBM between 1986 to 2007, with pathology data collected in a neuropathology bank (Laboratoire de Neuropathologie Raymond Escourolle, Paris, France). 
Genotyping of Polymorphisms
DNA was extracted from peripheral-blood samples with standard methods. CX3CR1 and CCL2 polymorphisms were genotyped with polymerase chain reaction-based amplification technology from Perkin Elmer (Applied Biosystems, Foster City, CA), as previously described. 23 The investigators who genotyped the samples were blinded to clinical and histologic data.
Immunostaining
Frozen tumor specimens were selected from archived tissue samples of surgically resected glioblastoma. Frozen sections were stained according to standard immunohistochemical procedures. 15 
Statistical Analysis
Statistical analyses were performed with SAS 8.2 (SAS Institute, Cary, NC) and Prism 4.01 (GraphPad Software, La Jolla, CA).
2 tests were used to compare the genotype distribution between the two groups (GBM and control), and odds ratios were calculated. The associations between qualitative variables were assessed with a 2 test, and the associations with continuous variables were assessed with a Kruskal-Wallis test.
Overall survival was defined as the time from diagnosis to death or last follow-up. Patients still alive at the last follow-up were censored in the analysis. Kaplan-Meier methods were used to obtain survival curves, and a two-sided log-rank test was used to compare strata. A multivariate Cox regression model was used to adjust the effect of genotype on patient survival for age, type of surgery, Karnofsky performance status (KPS), and postoperative treatment. Independent covariates were selected by stepwise methods. The proportional hazards assumption was checked for each explanatory variable by testing the effect of interaction with a time-dependent function. When the hypothesis of hazard proportionality was rejected, the effect of the variable on survival was modeled with a partition of the time axis (piecewise modeling). We studied the relation between genotype and CD68 ϩ cell-tumor infiltration with the MannWhitney U test and tested the influence of microglial infiltration on patient survival with a two-sided log-rank test, partitioning infiltration at its median value. The type I error rate for all analyses was set at 5%, and the Bonferroniadjusted significance level for the tests involving genotype was 0.0167 (three polymorphisms).
RESULTS
The clinical database included 230 patients who met the inclusion criteria. Table 1 lists demographic and clinical characteristics, along with survival. At the time of the study, 166 patients (72%) had died. Overall median survival was 14.9 months (95% CI, 13.2 to 16.7 months). As previously reported, age younger than 55 years, high performance status as assessed by KPS, and radiotherapy (with or without chemotherapy) were associated with longer survival. 22 Age and KPS were strongly correlated, however, with older patients having worse KPS (data not shown).
DNA samples from 230 patients with GBM and 525 healthy control subjects were genotyped for CX3CR1-V249I, -T280M, and CCL2-2518AϽG polymorphisms (Appendix Tables A1 and A2 , online only). Based on HapMap-released public data, all SNPs used in our study are tagged SNPs in European and African populations. Genotype frequencies did not deviate from Hardy-Weinberg equilibrium in any group. The absence of any difference in allelic or genotypic frequencies between the GBM group and the control group suggests that the CX3CR1 and CCL2 polymorphisms are not associated with the risk of GBM.
We then analyzed the impact of these polymorphisms on survival (Fig 1) . Patients with the CX3CR1-I249 variant allele survived longer than CX3CR1-V249 homozygous patients (median survival, 16.9 months v 13.5 months; P ϭ .0005; Fig 1A) . There was a tendency for patients with CX3CR1-M280 (Fig 1B) to survive longer (median survival, 17.1 months v 13.9 months), but this did not reach significance (P ϭ .1501), and the CCL2-2518G allele was not associated with survival at all (15.0 months v 14.4 months; Fig 1C) . As previously reported, 16 the CX3CR1-V249I and -T280M polymorphisms were in complete linkage disequilibrium and generated six combined genotypes and three haplotypes: VT, IT, and IM (data not shown). The overlap of the survival curves of patients with the IT (VT/IT ϩ IT/IT genotypes) and IM (IM/IM ϩ VT/IM ϩ IT/IM) haplotypes, with an overall median survival of 16.2 and 17.1 months, respectively (data not shown), suggests that the CX3CR1 M280 variant, which is exclusively associated with the CX3CR1 I249 variant, does not itself have any additional prognostic impact. The CX3CR1 M280 variant was therefore not considered further. Because hazard ratios (HRs) for age, surgery, and treatment vary with time, proportional hazards model could not be used for multivariate analysis. We therefore applied a time-dependent stepwise Cox multivariate regression (piecewise modeling), as presented in Table 2 . The adjusted HR associated with the CX3CR1-I249 allele remained significant after multivariate analysis, with an HR of 0.619 (95% CI, 0.451 to 0.850; P ϭ .0031). Survival was better in patients who underwent surgery and thus may be more sensitive to polymorphisms of the chemokine and their receptors. Indeed, in the patients with surgery (n ϭ 135), median survival was significantly higher for patients with the CX3CR1 variant allele than for those homozygous for the reference allele (20.7 and 14.4 months for CX3CR1-I249; P Ͻ .0001). No association was observed for the CCL2 gene (median survival, 15.9 and 17.0 months for the A and G alleles, respectively). For patients without surgery (n ϭ 95), however, median survival was not associated with any polymorphism tested (9.3 and 11.5 months or 10.5 and 9.8 months for patients with or without the common CX3CR1 and CCL2 variant alleles, respectively).
We sought to replicate these results in a retrospective series of 106 patients who had surgical resection. As in the first series, genotype frequencies did not deviate from Hardy-Weinberg equilibrium (data not shown) and neither allelic nor genotypic frequencies differed between the GBM group and the control group, thus confirming that the CX3CR1 and CCL2 polymorphisms were not associated with the risk of GBM. Again, patients with the CX3CR1-I249 variant allele survived longer than CX3CR1-V249 homozygous patients (median survival, 26.2 and 14.1 months, respectively; P ϭ .0001). CCL2-2518A/G was not associated with patient survival (19.1 and 19.2 Overall survival of patients with glioblastoma multiforme according to CX3CR1 and CCL2 genetic polymorphism. Kaplan-Meier survival curves were computed for patients with and without the common (A) CX3CR1-V249I, (B) CX3CR1-T280M, and (C) CCL2-2518AϾG variant alleles. Number of patients (n) and median survival (MS) are indicated for each group. P values were derived with the log-rank statistic.
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Because both the CX3CR1/CX3CL1 and CCR2/CCL2 pathways affect migration of myeloid lineage cells, we looked for interaction between polymorphisms for each pathway in the combined patient group (Appendix Fig A1, online only) . Mean survival for patients with variants of both genes was almost twice as long as for patients homozygous for the reference alleles (25.0 v 13.8 months; P ϭ .0001) but was not statistically different from that of patients carrying only the CX3CR1 variant allele (21.8 months; P ϭ .572). Patients with only the CCL2-2518 G allele had no better survival than homozygous patients (14.4 months; P ϭ .6306). These data indicate that the latter allele by itself had no beneficial effect.
To better understand how CX3CR1 alterations may contribute to survival in patients with GBM, we analyzed its expression in primary tumors (Fig 2) . Immunofluorescence studies revealed that all CX3CR1-positive cells were also positive for the microglial cell marker CD18 (Fig 2A) and that none costained with the astrocyte marker GFAP (Fig 2B) . These data indicate that CX3CR1 is expressed exclusively on microglial cells, as previously described, 25 and not on astrocytes or neurons. To determine whether microglial cell mobilization promotes tumor growth, we assessed microglial infiltration in 102 GMB samples by CD68 staining. CD68 ϩ cells accounted for a significantly higher percentage of the tumor in the patients homozygous for the reference CX3CR1 allele than in patients with the other CX3CR1 genotypes (Fig 2C) : 9.29% (range, 0.50% to 27.30%) of the tumor compared with 6.90% (range, 1.40% to 19.70%) for patients with at least one frequent variant allele (P ϭ .0249). CD68 ϩ cell infiltration of tumors was not correlated with patient survival in the overall patient group or in the CX3CR1 V249 or I249 subgroups.
DISCUSSION
Patients with GBM without therapy die within 4 months, whereas median survival in those receiving optimal treatment is approximately 15 months.
1 Survival nonetheless varies significantly between patients, and no reliable biomarker currently predicts prognosis in GBM. Here, we showed that the CX3CR1 chemokine receptor allelic variant known to alter microglial activity had a profound prognostic impact in GBM populations: median survival reached almost 2 years in patients carrying the frequent CX3CR1 variant. The association of this variant with microglial infiltration of the tumor suggests that it may affect functional microglial response. In addition, distributions of genotypes for CX3CR1 and CCL2 variants in patients with GBM and in controls were similar, indicating that there was no segregation of CX3CR1-I249 with the glioblastoma population. None of the polymorphisms tested was thus associated with disease risk. Taken together, these results support the hypothesis that CX3CR1 plays a pathogenic role in GBM.
Identifying factors that predict outcome in patients with GBM is a major challenge, and the prognostic impact of the local microenvironment, especially its microglial component, has not yet been investigated. Nonetheless, myeloid lineage cells play an important role in cancer progression, and their abundance is often associated with poor prognosis. 26, 27 The chemokine receptor CX3CR1 is widely expressed on cells of myeloid origin and their common progenitors, 28 and it is a ϩ immunostaining in specimens from patient with one or two common variant alleles of CX3CR1 and CCL2. CD68-immunoreactive cells were counted in tumor specimens from 102 patients; 48 were homozygous for the frequent allele of CX3CR1 and 54 carried at least one CX3CR1-I249 allele. The horizontal bars show median values, with P indicated above the solid symbols. P values were calculated with Mann-Whitney U test. MCI, microglial cell.
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The causal mechanism of these clinical effects may involve a delicate balance between excessive adhesion 19 and reduced chemotaxis. 15, 18 In this study, CX3CR1 was not expressed on tumor cells but only on CD68 ϩ cells (probably microglia or macrophages), and the common variant was associated with reduced microglial infiltration of the tumor. CX3CR1, which controls not only microglial mobilization 31 but also the extent of the cell protrusion that continuously samples the brain parenchyma, 32 is thus likely to participate in the neuroprotective and neurotoxic functions of activated microglia. 14, 25 In our study, the extent of tumor-associated microglial cells was not correlated with patient survival as previously reported. 33 However, tumors from patients homozygous for CX3CR1-V249 allele showed higher percentage of CD68 ϩ tumor-associated microglial cells. We and others previously showed that CX3CR1 rare alleles are functionally relevant 15, 18, 19 and alter cell migration and accumulation. In this study, CX3CR1-I249 survival advantage is only observed in patients who underwent surgery, suggesting a role of tumor cell characteristics in patient survival. However, tumoral gene alterations such as p53 expression, epidermal growth factor receptor amplification, P16/CDKN2A deletion, and loss of chromosome 10 did not provide any reliable prognostic markers for survival in patients with GBM. 22 Furthermore, the extent of tumor resection was not associated with patient survival, probably because in all cases, tumor resections were only partial and because GBM tumors were highly infiltrated. Alternative hypothesis may be related to antitumor immune response. Surgery by breaking the blood-brain barrier may favor activation of newly recruited leukocytes that have not been imprinted yet by the tolerogenic tumor environment. Analysis of the tumor mass or content as shown by the extent of CD68 ϩ microglial cell infiltration are likely to be poor prognostic markers of the beneficial effect of CX3CR1-I249 because host response to surgery was not initiated yet. Postsurgery indicators would be helpful in clarifying cellular mechanisms involved in CX3CR1-I249. It was recently shown that CX3CR1 mediates wound healing by promoting macrophage and fibroblast accumulation and function. 34 In addition, we and others previously showed that CX3CR1 is an important contributor to innate and adaptive immune responses. [35] [36] [37] CCL2 is another potent mediator of monocyte migration and macrophage differentiation. It is probably the chemokine found most frequently in tumors, 38 and its level of expression is correlated with macrophage infiltration, early relapse, and aggressiveness.
39-42 The CCL2-G2518 allelic variant is associated with enhanced CCL2 production 20 and may be a genetic risk factor for inflammatory diseases such as coronary artery diseases, 21, 43 asthma, 44 and autoimmune disorders. 45 However, these issues remain controversial. 46,47 Although recent studies report that patients with the CCL2-2518G allele are at increased risk of metastasis in breast cancer 48 and enhanced melanoma progression, 49 none associates the CCL2 polymorphism with the risk of cancer. Here, the CCL2 variant allele had no impact on either GBM risk or survival. This finding is rather counterintuitive, because CCL2-2518 is associated with enhanced CCL2 production, 20 and we would have expected enhanced mobilization of myeloid lineage cells to be associated with a detrimental clinical prognosis. We examined the possibility of a synergistic effect of both polymorphisms but did not detect any interactions between them. Biologic evidence suggests that these two chemokine axes may be connected. First, CCL2 regulates CX3CR1 expression, 50 and second, soluble CX3CL1 antagonizes the chemoattractant effect of CCL2 on monocytes. 51 Further studies investigating the intrinsic potencies of microglia from individuals with and without these variant alleles may reveal differential differentiation efficacy.
In conclusion, this is the first study, to our knowledge, to demonstrate that the host chemokine receptor gene CX3CR1 may be predictive of GBM survival. In addition, none of the polymorphisms tested was associated with disease risk. Taken together, our data suggest a strong relation between CX3CR1 variants, microglial infiltration, and survival of patients with GBM. An important aspect of this association is the relatively high frequency of the variant alleles, because half the patients carried the variant allele. This suggests the underlying mechanism is fairly widespread and that the predictive value of this marker may be useful in a large population of patients. Understanding the impact of these polymorphisms on GBM outcome could lead to novel therapeutic strategies targeting monocyte infiltration into glioblastomas.
